Catalysts
KPTI Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
KPTIKaryopharm Therapeutics Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum29
- Value65
- Quality100
- Risk resilience32
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 29/100 and sentiment — before the next covered event.
Updated Oct 22, 2026 · Sentiment 5.99%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | — | -$1.16 | — | — | $33.54M | — |
| Aug 13, 2026 | — | -$1.37 | -$2.32 | -69.3% | $32.19M | $33.43M |
| May 14, 2026 | — | -$1.45 | -$1.24 | +14.5% | $31.4M | $35.07M |
| Feb 12, 2026 | — | -$2.26 | -$5.68 | -151.3% | $35.1M | $34.08M |
| Nov 3, 2025 | — | -$3.47 | -$3.82 | -10.1% | $42.06M | $44.04M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight
The advanced endometrial cancer clinical trial analysis report delivers important insights into ongoing research of 26+ pipeline advanced endometrial cancer drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
Related Links
KPTI Catalysts FAQ
What are the next catalysts for KPTI stock?
KPTI's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move KPTI stock?
Upcoming events that could move KPTI include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could KPTI's next earnings report affect the stock?
KPTI's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive KPTI stock higher?
KPTI could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt KPTI stock?
KPTI could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.